Three-year follow-up of vaccine response in extremely preterm infants. 1998

R Khalak, and M E Pichichero, and C T D'Angio
Department of Pediatrics, Neonatology, Strong Children's Research Center, Rochester, New York 14642, USA.

OBJECTIVE To assess whether the adequate antibody response observed in former extremely premature infants after the primary series of immunizations is sustained after the first booster vaccines. METHODS Sixteen former extremely premature (<29 weeks, <1000 g at birth) and 17 former full-term (>37 weeks) infants had sera obtained for antibody titer measurement at 3 to 4 years of age. All had received the primary series and first booster vaccines for diphtheria, pertussis, tetanus, polio, and Haemophilus influenzae type b. Twelve preterm and 14 full-term children had completed the hepatitis B vaccine series. RESULTS At 3 to 4 years of age, former preterm and full-term children had similar geometric mean titer (GMT) values of antibodies to tetanus, diphtheria, and pertussis. Preterm children had a lower GMT value of Haemophilus polyribosylribitol phosphate (PRP) antibody than did full-term children (0.99 vs 3.06 microg/mL). Fifty percent of preterm and 88% of full-term children had PRP antibody >1.0 microg/mL; 100% of preterm and 94% of full-term children had anti-PRP titers >0.15 microg/mL. GMT values of neutralizing antibodies to polio serotypes 1 and 2 were similar, with 94% to 100% of both groups above protective levels (>/=1:8). The difference in GMT values of polio serotype 3 approached significance (29 vs 73); fewer preterm children had protective titer values (75% vs 100%). Among children vaccinated against hepatitis B, 75% of preterm and 71% of full-term children were protected (10 mIU/mL). CONCLUSIONS Preterm children immunized at the recommended chronological ages displayed antibody responses similar to those for full-term children for most immunizing antigens. Responses to PRP and polio serotype 3 were less robust than those of full-term children.

UI MeSH Term Description Entries
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D011055 Poliovirus Vaccine, Oral A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed) Sabin Vaccine,Oral Poliovirus Vaccine,Vaccine, Oral Poliovirus,Vaccine, Sabin
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine
D015721 Diphtheria-Tetanus-Pertussis Vaccine A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough. DPT Vaccine,DTP Vaccine,DTwP Vaccine,Diphtheria-Pertussis-Tetanus Vaccine,Di-Te-Per Vaccine,Di Te Per Vaccine,Diphtheria Pertussis Tetanus Vaccine,Diphtheria Tetanus Pertussis Vaccine,Vaccine, DPT,Vaccine, DTP,Vaccine, DTwP,Vaccine, Di-Te-Per,Vaccine, Diphtheria-Pertussis-Tetanus,Vaccine, Diphtheria-Tetanus-Pertussis
D017325 Hepatitis B Vaccines Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced. Hepatitis B Vaccine,Vaccine, Hepatitis B,Vaccines, Hepatitis B

Related Publications

R Khalak, and M E Pichichero, and C T D'Angio
March 2002, Pediatrics,
R Khalak, and M E Pichichero, and C T D'Angio
June 2010, Neonatology,
R Khalak, and M E Pichichero, and C T D'Angio
January 2018, Autism research and treatment,
R Khalak, and M E Pichichero, and C T D'Angio
October 1988, Developmental medicine and child neurology,
R Khalak, and M E Pichichero, and C T D'Angio
July 2002, Archives of disease in childhood. Fetal and neonatal edition,
R Khalak, and M E Pichichero, and C T D'Angio
December 2015, Early human development,
R Khalak, and M E Pichichero, and C T D'Angio
December 2012, Pediatrics,
R Khalak, and M E Pichichero, and C T D'Angio
June 2017, Pediatrics,
R Khalak, and M E Pichichero, and C T D'Angio
July 1998, Vaccine,
Copied contents to your clipboard!